Corcept Historical Income Statement

CORT Stock

USD 57.54 1.62 2.90%

Historical analysis of Corcept Therapeutics income statement accounts such as Selling General Administrative of 193.1 M, Research Development of 193.6 M or Other Operating Expenses of 393.8 M can show how well Corcept Therapeutics Incorporated performed in making a profits. Evaluating Corcept Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Corcept Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Corcept Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Corcept Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

About Corcept Income Statement Analysis

Corcept Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Corcept Therapeutics shareholders. The income statement also shows Corcept investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Corcept Therapeutics Income Statement Chart

At this time, Corcept Therapeutics' Net Income is comparatively stable compared to the past year. Income Tax Expense is likely to gain to about 19.3 M in 2024, whereas Non Operating Income Net Other is likely to drop slightly above 577.9 K in 2024.

Selling General Administrative Research Development Other Operating Expenses Total Operating Expenses Non Operating Income Net Other Tax Provision

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Corcept Therapeutics. It is also known as Corcept Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Most accounts from Corcept Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Corcept Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

	2021	2022	2023	2024 (projected)
Other Operating Expenses	241.5M	289.2M	375.1M	393.8M
Research Development	113.9M	131.0M	184.4M	193.6M

Other Operating Expenses Research Development

Corcept Therapeutics income statement Correlations

	Interest Expense	Selling General Administrative	Research Development	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Net Income	Income Tax Expense	Depreciation And Amortization	Selling And Marketing Expenses	Income Before Tax	Total Other Income Expense Net	Total Revenue	Gross Profit	Cost Of Revenue	Net Income From Continuing Ops	Non Operating Income Net Other	Interest Income	Net Interest Income	Tax Provision	Reconciled Depreciation	Extraordinary Items
Interest Expense		0.58	0.57	0.58	0.52	0.52	0.52	0.58	0.32	0.61	0.56	-0.27	0.45	0.35	0.57	0.57	-0.25	0.36	0.54	0.37	0.45	0.65	0.61	0.26
Selling General Administrative	0.58		0.99	1.0	0.86	0.86	0.86	1.0	0.81	0.37	0.64	-0.69	0.36	0.86	0.98	0.98	0.0	0.82	0.3	0.71	0.88	0.86	0.85	0.68
Research Development	0.57	0.99		1.0	0.86	0.86	0.86	1.0	0.79	0.43	0.62	-0.71	0.31	0.89	0.98	0.98	0.04	0.8	0.33	0.74	0.91	0.88	0.85	0.71
Other Operating Expenses	0.58	1.0	1.0		0.87	0.87	0.87	1.0	0.81	0.4	0.63	-0.7	0.33	0.88	0.98	0.98	0.03	0.82	0.32	0.73	0.9	0.87	0.85	0.69
Operating Income	0.52	0.86	0.86	0.87		1.0	1.0	0.86	0.94	0.34	0.78	-0.36	0.24	0.66	0.94	0.94	0.16	0.94	0.6	0.37	0.66	0.94	0.86	0.36
Ebit	0.52	0.86	0.86	0.87	1.0		1.0	0.86	0.94	0.34	0.78	-0.36	0.24	0.66	0.94	0.94	0.16	0.94	0.6	0.37	0.66	0.94	0.86	0.36
Ebitda	0.52	0.86	0.86	0.87	1.0	1.0		0.86	0.94	0.34	0.79	-0.36	0.24	0.66	0.94	0.94	0.16	0.94	0.6	0.37	0.66	0.94	0.86	0.35
Total Operating Expenses	0.58	1.0	1.0	1.0	0.86	0.86	0.86		0.8	0.4	0.63	-0.7	0.33	0.88	0.98	0.98	0.03	0.81	0.32	0.73	0.9	0.87	0.85	0.7
Net Income	0.32	0.81	0.79	0.81	0.94	0.94	0.94	0.8		0.02	0.66	-0.36	0.23	0.63	0.88	0.88	0.15	1.0	0.46	0.32	0.63	0.79	0.74	0.36
Income Tax Expense	0.61	0.37	0.43	0.4	0.34	0.34	0.34	0.4	0.02		0.43	-0.24	-0.03	0.36	0.39	0.39	0.17	0.01	0.44	0.39	0.36	0.59	0.49	0.24
Depreciation And Amortization	0.56	0.64	0.62	0.63	0.78	0.78	0.79	0.63	0.66	0.43		0.0	0.22	0.28	0.71	0.71	0.07	0.66	0.48	0.04	0.29	0.76	0.93	0.02
Selling And Marketing Expenses	-0.27	-0.69	-0.71	-0.7	-0.36	-0.36	-0.36	-0.7	-0.36	-0.24	0.0		-0.11	-0.87	-0.6	-0.6	-0.06	-0.36	0.07	-0.93	-0.88	-0.4	-0.34	-0.8
Income Before Tax	0.45	0.36	0.31	0.33	0.24	0.24	0.24	0.33	0.23	-0.03	0.22	-0.11		0.11	0.31	0.31	-0.92	0.32	0.17	0.1	0.2	0.27	0.23	0.11
Total Other Income Expense Net	0.35	0.86	0.89	0.88	0.66	0.66	0.66	0.88	0.63	0.36	0.28	-0.87	0.11		0.83	0.83	0.18	0.63	0.25	0.92	0.99	0.7	0.6	0.86
Total Revenue	0.57	0.98	0.98	0.98	0.94	0.94	0.94	0.98	0.88	0.39	0.71	-0.6	0.31	0.83		1.0	0.08	0.89	0.43	0.62	0.84	0.92	0.88	0.6
Gross Profit	0.57	0.98	0.98	0.98	0.94	0.94	0.94	0.98	0.88	0.39	0.71	-0.6	0.31	0.83	1.0		0.08	0.89	0.43	0.62	0.84	0.92	0.88	0.6
Cost Of Revenue	-0.25	0.0	0.04	0.03	0.16	0.16	0.16	0.03	0.15	0.17	0.07	-0.06	-0.92	0.18	0.08	0.08		0.06	0.07	0.09	0.1	0.11	0.1	0.08
Net Income From Continuing Ops	0.36	0.82	0.8	0.82	0.94	0.94	0.94	0.81	1.0	0.01	0.66	-0.36	0.32	0.63	0.89	0.89	0.06		0.47	0.32	0.63	0.8	0.74	0.36
Non Operating Income Net Other	0.54	0.3	0.33	0.32	0.6	0.6	0.6	0.32	0.46	0.44	0.48	0.07	0.17	0.25	0.43	0.43	0.07	0.47		0.05	0.25	0.68	0.42	-0.07
Interest Income	0.37	0.71	0.74	0.73	0.37	0.37	0.37	0.73	0.32	0.39	0.04	-0.93	0.1	0.92	0.62	0.62	0.09	0.32	0.05		0.93	0.46	0.4	0.92
Net Interest Income	0.45	0.88	0.91	0.9	0.66	0.66	0.66	0.9	0.63	0.36	0.29	-0.88	0.2	0.99	0.84	0.84	0.1	0.63	0.25	0.93		0.7	0.61	0.88
Tax Provision	0.65	0.86	0.88	0.87	0.94	0.94	0.94	0.87	0.79	0.59	0.76	-0.4	0.27	0.7	0.92	0.92	0.11	0.8	0.68	0.46	0.7		0.86	0.4
Reconciled Depreciation	0.61	0.85	0.85	0.85	0.86	0.86	0.86	0.85	0.74	0.49	0.93	-0.34	0.23	0.6	0.88	0.88	0.1	0.74	0.42	0.4	0.61	0.86		0.38
Extraordinary Items	0.26	0.68	0.71	0.69	0.36	0.36	0.35	0.7	0.36	0.24	0.02	-0.8	0.11	0.86	0.6	0.6	0.08	0.36	-0.07	0.92	0.88	0.4	0.38

Click cells to compare fundamentals

Corcept Therapeutics Account Relationship Matchups

Corcept Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	5.1M	5.6M	3.6M	3.6M	4.1M	4.3M
Selling General Administrative	100.4M	105.3M	122.4M	152.8M	184.3M	193.1M
Research Development	89.0M	114.8M	113.9M	131.0M	184.4M	193.6M
Other Operating Expenses	194.9M	225.7M	241.5M	289.2M	375.1M	393.8M
Operating Income	111.6M	128.2M	124.5M	112.6M	107.3M	112.6M
Ebit	111.6M	128.2M	124.5M	112.6M	107.3M	112.6M
Ebitda	113.8M	130.4M	127.5M	115.6M	108.3M	113.7M
Total Operating Expenses	189.4M	220.1M	236.2M	283.8M	368.6M	387.0M
Net Income	94.2M	106.0M	112.5M	101.4M	106.1M	111.4M
Income Tax Expense	22.5M	25.6M	12.5M	14.8M	18.4M	19.3M
Depreciation And Amortization	2.2M	2.2M	3.1M	3.0M	1.0M	770.3K
Income Before Tax	116.7M	131.6M	125.0M	116.2M	124.6M	130.8M
Total Other Income Expense Net	5.1M	3.4M	529K	3.6M	17.3M	18.1M
Total Revenue	306.5M	353.9M	366.0M	401.9M	482.4M	506.5M
Gross Profit	301.0M	348.3M	360.7M	396.5M	475.9M	499.7M
Cost Of Revenue	5.5M	5.6M	5.3M	5.4M	6.5M	5.7M
Net Income From Continuing Ops	94.2M	106.0M	112.5M	101.4M	106.1M	111.4M
Non Operating Income Net Other	2.7M	5.1M	3.4M	529K	608.4K	577.9K
Net Income Applicable To Common Shares	94.2M	106.0M	112.5M	101.3M	116.5M	122.3M
Interest Income	5.1M	3.4M	529K	3.6M	17.3M	18.1M
Net Interest Income	5.1M	3.4M	529K	3.6M	17.3M	18.1M
Tax Provision	22.5M	25.6M	12.5M	14.8M	18.4M	19.3M
Reconciled Depreciation	2.2M	2.2M	3.1M	3.0M	2.4M	2.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Corcept Stock Analysis

When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Corcept Historical Income Statement

About Corcept Income Statement Analysis

Corcept Therapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Tax Provision

Corcept Therapeutics income statement Correlations

Corcept Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Corcept Therapeutics income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Corcept Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Operating Expenses	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Selling General Administrative
Other Operating Expenses	+ 1.0	Research Development
Total Operating Expenses	+ 1.0	Research Development
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income

Interest Income	- 0.93	Selling And Marketing Expenses
Cost Of Revenue	- 0.92	Income Before Tax
Net Interest Income	- 0.88	Selling And Marketing Expenses
Total Other Income Expense Net	- 0.87	Selling And Marketing Expenses
Extraordinary Items	- 0.8	Selling And Marketing Expenses
Selling And Marketing Expenses	- 0.71	Research Development